|187.49||+0.5500||+0.29%||Vol 209.56K||1Y Perf -3.92%|
|Dec 1st, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||245.60||Analyst Rating||Strong Buy 1.44|
|Potential %||30.99||Finscreener Ranking||★★★★ 54.08|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★ 45.69|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★+ 47.48|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||24.93||Earnings Rating||Strong Buy|
|Market Cap||19.61B||Earnings Date||8th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-3.16|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||161.40K|
|Avg. Monthly Volume||220.39K|
|Avg. Quarterly Volume||206.59K|
BeiGene Ltd. (NASDAQ: BGNE) stock closed at 186.94 per share at the end of the most recent trading day (a 2.08% change compared to the prior day closing price) with a volume of 186.74K shares and market capitalization of 19.61B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5300 people. BeiGene Ltd. CEO is John V. Oyler.
The one-year performance of BeiGene Ltd. stock is -3.92%, while year-to-date (YTD) performance is -15%. BGNE stock has a five-year performance of 21.94%. Its 52-week range is between 156.56 and 280.6199, which gives BGNE stock a 52-week price range ratio of 24.93%
BeiGene Ltd. currently has a PE ratio of -11.60, a price-to-book (PB) ratio of 5.48, a price-to-sale (PS) ratio of 24.68, a price to cashflow ratio of 605.70, a PEG ratio of -0.52, a ROA of -37.57%, a ROC of -44.67% and a ROE of -56.13%. The company’s profit margin is -86.01%, its EBITDA margin is -146.50%, and its revenue ttm is $1.04 Billion , which makes it $9.96 revenue per share.
Of the last four earnings reports from BeiGene Ltd., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-3.16 for the next earnings report. BeiGene Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BeiGene Ltd. is Strong Buy (1.44), with a target price of $245.6, which is +30.99% compared to the current price. The earnings rating for BeiGene Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BeiGene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BeiGene Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.35, ATR14 : 6.56, CCI20 : -28.96, Chaikin Money Flow : -0.09, MACD : 0.54, Money Flow Index : 48.40, ROC : -6.11, RSI : 51.43, STOCH (14,3) : 29.91, STOCH RSI : 1.00, UO : 51.77, Williams %R : -70.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BeiGene Ltd. in the last 12-months were: Capital Advisors, Ltd. Hillhouse (Sold 4 154 817 shares of value $823 480 568 ), HHLR ADVISORS, LTD. (Sold 4 154 817 shares of value $823 490 197 ), Oyler John (Sold 8 552 shares of value $2 127 538 ), Sanders Corazon (Sold 100 shares of value $18 074 ), Sanders Corazon (Corsee) D. (Sold 578 shares of value $105 381 ), Wang Julia Aijun (Sold 1 312 shares of value $238 341 ), Wang Lai (Sold 3 019 shares of value $583 636 ), Wang Xiaodong (Sold 811 620 shares of value $-8 793 ), Wang Xiaodong (Sold 61 771 shares of value $14 144 437 ), Wu Xiaobin (Sold 7 253 shares of value $1 565 482 )
Mon, 16 Oct 2023 13:00 GMT Analysts Top Healthcare Picks: BeiGene (BGNE), Moderna (MRNA)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.